Cancer 2010, 116(11 Suppl):2794–2805.PubMedCrossRef 7. Gong Y,

Huo L, www.selleckchem.com/products/BIRB-796-(Doramapimod).html Liu P, Sneige N, Sun X, Ueno NT, Lucci A, Buchholz TA, PLX-4720 datasheet Valero V, Cristofanilli M: Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Cancer 2011, 117(24):5476–5484.PubMedCrossRef 8. Mu Z, Li H, Fernandez SV, Alpaugh KR, Zhang R, Cristofanilli M: EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells. J Exp Clin Cancer Res 2013, 32(1):70.PubMedCentralPubMed 9. Sparmann A, van Lohuizen M: Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 2006, 6(11):846–856.PubMedCrossRef 10. Ezhkova E, Pasolli HA, Parker JS, Stokes N, Su IH, Hannon G, Tarakhovsky A, Fuchs E: Ezh2 orchestrates gene expression for the stepwise

differentiation GDC-973 of tissue-specific stem cells. Cell 2009, 136(6):1122–1135.PubMedCentralPubMedCrossRef 11. Chang CJ, Yang JY, Xia W, Chen CT, Xie X, Chao CH, Woodward WA, Hsu JM, Hortobagyi GN, Hung MC: EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling. Cancer Cell 2011, 19(1):86–100.PubMedCentralPubMedCrossRef 12. Woodward WA, Buchholz TA: The role of locoregional therapy in inflammatory breast cancer. Semin Oncol 2008, 35(1):78–86.PubMedCrossRef 13. Woodward WA, Debeb BG, Xu W, Buchholz TA: Overcoming radiation resistance in inflammatory breast cancer. Cancer 2010, 116(11 Suppl):2840–2845.PubMedCrossRef 14. Saigal K, Hurley J, Takita C, Reis IM, Zhao W, Rodgers SE, Wright JL: Risk factors for locoregional failure in patients with inflammatory breast cancer treated with trimodality therapy. Clin Breast Cancer 2013, 13(5):335–343.PubMed 15. Dong Methocarbamol Q, Oh JE, Chen W, Kim R, Kim RH, Shin KH, McBride WH, Park NH, Kang MK: Radioprotective effects

of Bmi-1 involve epigenetic silencing of oxidase genes and enhanced DNA repair in normal human keratinocytes. J Invest Dermatol 2011, 131(6):1216–1225.PubMedCrossRef 16. Alimova I, Birks DK, Harris PS, Knipstein JA, Venkataraman S, Marquez VE, Foreman NK, Vibhakar R: Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells. Neuro Oncol 2013, 15(2):149–160.PubMedCentralPubMedCrossRef 17. Xia H, Yu CH, Zhang Y, Yu J, Li J, Zhang W, Zhang B, Li Y, Guo N: EZH2 silencing with RNAi enhances irradiation-induced inhibition of human lung cancer growth in vitro and in vivo. Oncol Lett 2012, 4(1):135–140.PubMedCentralPubMed 18. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444(7120):756–760.PubMedCrossRef 19.